French biotech investors launch spin-out alliance

Argobio SAS has been kicked off with €50m of committed capital from Kurma Partners, and the state bank Bpifrance. Co-investors include Angelini Pharma, Evotec, and the Institut Pasteur. The newly created vehicle has the mission to create at least five ambitious biotech companies over the next five years sourcing innovative early-stage projects from renowned European academic research institutions.

Argobio, which has initial committments of  €50m will focus on the most lucrative medically underserved therapeutic areas, namely rare diseases, neurological disorders, oncology, and immunology. It willlook to develop promising platform technologies for therapeutic products. The investors will have an option to invest in the biotech companies created by Argobio.
 
Argobio will identify, select, and incubate these projects up to company creation, providing broad expertise in the discovery and development of innovative therapeutic products from its team of highly experienced biotech entrepreneurs. The team will be led by Yves Ribeill, Neill Mackenzie and Rémi Soula. Thierry Laugel, Managing Partner at Kurma Partners will be appointed President of Argobio, and Laurent Arthaud, Director of the Biotech and Ecotech investment of Bpifrance, will be appointed Chairman of the Supervisory Board.
 

NewCap
Nicolas Merigeau
Media Relations
Phone nb.: +33 (0)1 44 71 94 98
Email: nmerigeau@newcap.fr
Unsubscribe